TY -的T1 -让简单的事情复杂ing anti-inflammatory reliever therapy JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00267-2020 VL - 55 IS - 4 SP - 2000267 AU - Lipworth, Brian AU - Kuo, Chris RuiWen AU - Chan, Rory Y1 - 2020/04/01 UR - //www.qdcxjkg.com/content/55/4/2000267.abstract N2 - We appreciated reading the eloquent editorial from Beasley et al. [1], who make a cogent evidence-based case for using budesonide/formoterol (BUD/FM) on demand (p.r.n.) as the preferred asthma reliever, in keeping with the latest GINA guidelines. They proffer what appears at first sight to be a pragmatic stepwise treatment algorithm and associated action plan for using BUD/FM p.r.n. as anti-inflammatory reliever (AIR)±maintenance therapy across Global Initiative for Asthma steps 1 to 3.Use more budesonide/formoterol when you need it, and less when you don't http://bit.ly/2PKsCOH ER -